The 'Outperform' rating maintained by BMO Capital indicates that the analyst expects Nuvalent to do better than the market average. The increase in the price target from $73 to $79 suggests that the analyst sees potential for the stock's price to rise in the short term. This is likely to have a positive impact on the stock's price.